Wedbush Lowers Geron Price Target to $5 From $6, Keeps Outperform Rating
Dow Jones Newswires reports Wedbush cut its Geron price target to $5.00 from $6.00 and maintained its Outperform rating on the biotech stock.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Dow Jones Newswires reports that Wedbush has lowered its price target on Geron to $5.00 per share from $6.00. The brokerage kept its Outperform rating on the stock, according to the ratings data cited in the report.
why it matters
A single brokerage's target change is usually a minor market event. It reflects one analyst's valuation view rather than new company results, so its effect on the stock is typically limited.
tags
instruments
sources
- Geron Price Target Cut to $5.00/Share From $6.00 by Wedbush — Dow Jones Newswires, 29 October 2026 at 14:51 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗